Table 1: Characteristics of patients.
Number of patients (%) | |
Total | 63 |
Median age, years (range) | 64 (40-80) |
Hormone receptor status | |
ER-positive and/or PgR-positive | 35 (56%) |
ER-negative and PgR-negative | 28 (44%) |
HER2 status | |
IHC 3+ | 56 (89%) |
IHC 2+ and ISH positive | 7 (11%) |
Stage IV | 18 (29%) |
Recurrence | 45 (71%) |
Median disease free interval, months (range) | 29 (2-104) |
< 2 years | 19 (42%) |
2-5 years | 19 (42%) |
≥ 5 years | 7 (16%) |
Site of disease involvement | |
Visceral | 43 (67%) |
Nonvisceral | 21 (33%) |
Metastatic site | |
Lung | 28 (44%) |
Liver | 21 (33%) |
Bone | 25 (40%) |
Brain | 14 (22%) |
Lymph node | 31 (49%) |
Other | 30 (48%) |
IHC: immunohistochemistry; ISH: in situ hybridization.